))
ETI (CFTR Triple Therapy): Clinical Opportunities
Manage episode 341189922 series 2902538
Innhold levert av eCysticFibrosis Review and ECysticFibrosis Review. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av eCysticFibrosis Review and ECysticFibrosis Review eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit?
Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
72 episoder
Del
